TUESDAY, SEPTEMBER 27, 2016

Novavax announced positive preclinical trial for H7N9 influenza vaccine

Novavax announced on July 29 a positive preclinical trial for its virus-like particle vaccine candidate against the H7N9 Influenza A, which protected 100 percent of the mice studied in the trial from infection.

The data from the study was published in the journal Vaccine. Researchers in the study used three control groups to test the efficacy of the new vaccine candidate; the control groups used a VLP vaccine against H7N3, a VLP vaccine against H5N1 and a placebo. Some of the immunizations also contained Isomatrix, an adjuvant based on saponin.

Researchers from the study conducted the preclinical trial based on a mouse model. During the study, researchers saw an increase in the hemagglutination-inhibition antibody response towards H7N9.

The H7N9 vaccine also seemed to cross-protect against H7N3. When used in conjunction with the adjuvant, a 3-4times higher rate of efficacy was seen.

One hundred percent of the mice involved in the study were fully protected from a deadly murine version of the H7N9 virus.

"Alongside our positive clinical results with our H5N1 VLP vaccine candidate from last October these recently gathered animal data against H7N9 influenza A give another confirmation that the Novavax vaccine platform deserves to play a key role in emerging pandemic threats," Novavax President and CEO Stanley C. Erck said. "We remain focused on expanding this campaign as evidenced by the start of the first H7N9 vaccine clinical trial."